Pharma BD Deal Intelligence
Catalent acquired Paragon Bioservices for $1.2 billion in cash, adding viral vector (AAV/lentivirus) capabilities to support gene therapy and biologics CDMO services. Announced April 15, 2019; closed May 17, 2019. The thesis was validated post-close: the former Paragon site in Harmans, Maryland (near BWI) became a commercial viral-vector manufacturing hub for Novartis's Zolgensma and, after FDA approval in 2023, the drug-substance site for Sarepta's Elevidys. Catalent — including the former-Paragon gene therapy platform — was subsequently acquired by Novo Holdings in an all-cash deal (~$16.5B enterprise value, $63.50/share) completed December 18, 2024, with the stock delisted from the NYSE. In August 2025 Catalent announced ~350 layoffs at the Harmans viral-vector site citing a demand shift from a large customer.
Assessment window: 5yr post-close.